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ABSTRACT Meropenem-vaborbactam (MEV) is a novel carbapenem– beta-lactamase
inhibitor combination antibiotic approved by the U.S. Food and Drug Administration
(FDA) for treatment of complicated urinary tract infections, including pyelonephritis,
in adults. In this study, we evaluated the performance of Etest MEV (bioMérieux,
Marcy l’Etoile, France) compared to that of broth microdilution for 629 Enterobacte-
rales and 163 Pseudomonas aeruginosa isolates. According to CLSI/FDA breakpoints,
13 Enterobacterales isolates (12 clinical and 1 challenge) were resistant to MEV. Over-
all, Etest MEV demonstrated 92.4% essential agreement (EA), 99.2% category agree-
ment (CA), 0% very major errors (VME), 0% major errors (ME), and 0.8% minor errors
(mE) with clinical and challenge isolates of Enterobacterales. Individual species dem-
onstrated EA rates of 80%, with the exception of Proteus mirabilis, for which clini-
cal and challenge isolates demonstrated 34.3% EA, 97.1% CA, 0% ME, and 2.9% mE,
precluding the use of Etest MEV with this species. Excluding P. mirabilis, MEV Etest
MEV demonstrated 95.8% EA, 99.3% CA, 0% VME, 0% ME, and 0.7% mE with Entero-
bacterales isolates. When evaluated using European Committee on Antimicrobial Sus-
ceptibility Testing (EUCAST) breakpoints, Etest MEV performance with clinical (16
MEV resistant) and challenge (12 MEV resistant) isolates of Enterobacterales (exclud-
ing P. mirabilis) and P. aeruginosa demonstrated an unacceptably high VME rate of
7.1% despite 95.2% EA, 99.2% CA, and 0.5% ME compared to the reference method.
In conclusion, we report that Etest MEV is accurate and reproducible for MEV sus-
ceptibility testing for P. aeruginosa and Enterobacterales, with the exception of P. mi-
rabilis, using CLSI/FDA breakpoints. Etest MEV should not be used with P. mirabilis
due to unacceptable analytical performance.
KEYWORDS susceptibility testing, gradient diffusion, meropenem-vaborbactam
Meropenem-vaborbactam (MEV) is a novel beta-lactamase combination agentcomposed of a carbapenem, meropenem, and a cyclic boronic acid compound
and novel -lactamase inhibitor, vaborbactam. MEV was approved by the U.S. Food and
Drug Administration (FDA) for treatment of complicated urinary tract infections (cUTI),
including pyelonephritis, in adults after it was demonstrated to be noninferior to
piperacillin-tazobactam for treatment of cUTI (1, 2). Recently, therapy with MEV was also
shown to result in reduced all-cause mortality and a statistically significant increase in
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cure rates for serious infections due to carbapenem-resistant Enterobacterales (CRE),
including cUTI/pyelonephritis, complicated intraabdominal infection (cIAI), health care/
ventilator-associated bacterial pneumonia (HCABP/VABP), and/or bloodstream infec-
tion, compared to the best alternative therapy (3).
Vaborbactam was developed to have potent activity against Klebsiella pneumoniae
carbapenemases (KPC) but also has activity against strains producing Ambler class A
enzymes such as imipenemase (IMI) and Guiana extended-spectrum (GES) enzymes and
class C carbapenemases. However, MEV lacks activity against metallo--lactamases
(Ambler class B) or Ambler class D/OXA-type enzymes and thus is not clinically useful
in the treatment of organisms that produce these enzymes (4). Additionally, MEV does
not have improved in vitro activity against carbapenem-resistant Pseudomonas aerugi-
nosa, Acinetobacter spp., and other nonfermenting Gram-negative bacilli compared to
meropenem alone, as a result of the predominance of noncarbapenemase mechanisms
of resistance in these species and the presence of Ambler class B (P. aeruginosa) or class
D (Acinetobacter spp.) enzymes most commonly when carbapenemases are present.
Resistance to MEV among Enterobacterales has been reported even among KPC-
producing CRE; thus, susceptibility testing is appropriate in settings where the pre-
scription of this agent is anticipated. Additionally, in the absence of molecular diag-
nostics in many clinical laboratories, the availability of practical susceptibility testing is
critical for detection of MEV-resistant organisms when considering MEV for treatment
of meropenem-resistant Enterobacterales. Our objective was to conduct a multicenter
evaluation of the analytical performance characteristics of Etest MEV (bioMérieux,
Marcy l’Etoile, France) compared to the Clinical and Laboratory Standards Institute
(CLSI) reference broth microdilution (BMD). Etest MEV was recently cleared for in vitro
diagnostic (IVD) use by the U.S. Food and Drug Administration (FDA) (5).
MATERIALS AND METHODS
Ethics. Each study site performing testing on clinical strains acquired local institutional review board
approval or waiver prior to study initiation.
Setting. Testing was performed at the University of California—Los Angeles Medical Center (UCLA)
(Los Angeles, CA), Washington University School of Medicine (WU) (St. Louis, MO), University Hospital of
Wales (Cardiff) (Wales, UK), and bioMérieux SA (Marcy) (Marcy l’Etoile, France). Challenge and quality
control (QC) studies took place at Marcy, while clinical, reproducibility, and quality control studies took
place at UCLA, WU, and Cardiff.
Susceptibility testing methodology. For Etest MEV, a visual calibrator was used to prepare a 0.5
McFarland suspension (for nonmucoid isolates) in 0.85% sterile saline from 18 to 24 h of colony growth
on blood agar. All mucoid isolates were tested using a 1.0 McFarland standard inoculum. Within 15 min
of preparation, a sterile cotton swab moistened with the standardized bacterial suspension was inocu-
lated to BBL Mueller-Hinton II agar plates (BD, Sparks, MD), and Etest strips were applied to plates
manually or automatically using a Retro C80 rota-plater and/or a Nema C88 vacuum pen (bioMérieux,
Durham, NC). Plates were incubated in ambient air at 35  2°C and read after 16 to 20 h of incubation.
Using reflected light, the MIC was read where the elliptical zone of inhibition intersected the Etest strip
or rounded up to the nearest doubling dilution as described in the Etest MEV instructions for use (6). For
the broth microdilution (BMD) method, 96-well microtiter plates with 0.1 ml diluted antimicrobial
suspension per well, consisting of 2-fold dilutions of meropenem ranging from 0.004 to 64 g/ml and
vaborbactam fixed at 8 g/ml in cation-adjusted Mueller-Hinton broth, were prepared by bioMérieux
and provided to each site; panels were stored frozen at – 60°C. Prior to use, BMD panels were thawed
completely at room temperature for 30 min to 1 h. Using a repeater pipette, BMD panels were inoculated
with 0.05 ml of a 100-fold dilution in cation-adjusted BBL Mueller-Hinton II broth (BD, Sparks, MD) of the
same 0.5 McFarland suspension used for Etest MEV and incubated at 35  2°C in ambient air for 16 to
20 h. The MIC was read as the lowest concentration of MEV showing complete inhibition of growth as
described in CLSI document M7-A10 (7). Growth from BMD was inoculated to blood agar and assessed
for purity after 20 to 24 and 44 to 48 h of incubation. Inoculum density checks were performed with
quality control strains, reproducibility strains, and 10% of fresh clinical isolates. Briefly, a 100-l aliquot
of a 1:1,000 dilution of the growth control from broth microdilution panels was plated to blood agar and
incubated at 35  2°C in ambient air for 18 to 48 h. Colony counts after incubation were recorded and
used to calculate the final inoculum density.
Reproducibility study. Twelve on-scale stock strains provided by bioMérieux (Enterobacterales,
n  10; Pseudomonas aeruginosa, n  2) were each tested three times from a separate inoculum for 3
days at the UCLA, WU, and Cardiff study sites. Isolates were subcultured twice on blood agar before
testing. A 0.5 McFarland suspension prepared in 0.85% sterile saline of each strain was used for the Etest,
and an inoculum density check was performed. Tests from all three sites were used to establish a modal
value for each strain. Test results within 1 doubling dilution were deemed acceptable and were used
to calculate the reproducibility rate as the percentage of total tests performed with essential agreement
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(EA). Best-case calculations for reproducibility assumed off-scale values within one doubling dilution of
the mode, while worst-case reproducibility assumed that off-scale calculations were not within one
doubling dilution.
QC study. Quality control (QC) testing was performed at each site every day that testing was set up,
and a minimum of 20 times at each study site, with the following organisms: Escherichia coli ATCC 25922,
E. coli ATCC 35218, Klebsiella pneumoniae ATCC 700603, K. pneumoniae ATCC BAA-1705, and P. aerugi-
nosa ATCC 27853. The QC ranges described in CLSI supplement M100 (28th edition) (8) were applied on
each day of clinical or challenge testing, and an inoculum density check was conducted with all QC tests
according to CLSI document M7-A10 (7) and supplement M100 (28th edition) (8) guidelines. Results were
considered invalid if QC results were unacceptable. Quality control performance was calculated as the
percentage of total results within the expected range.
Clinical and challenge study. Seven hundred four clinical isolates of Enterobacterales and P.
aeruginosa and 88 challenge isolates were evaluated for MEV susceptibility using Etest MEV and
reference BMD simultaneously according to the methods described above. Clinical isolates were tested
at the UCLA (n  242), WU (n  240), and Cardiff (n  222), sites while challenge isolate testing was
performed entirely at the Marcy site. All clinical isolates were recovered from clinical cultures submitted
to the clinical laboratory as part of standard care and were identified to the genus and species levels by
the matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) (Vitek
MS), Vitek 2 (bioMérieux), or API identification (bioMérieux) system per the procedures at each clinical
study site. Only one isolate per species per patient could be included, and study personnel were blinded
to the susceptibility results for clinical isolates. A target of 10 to 50 isolates representing each of the
species indicated for use was set for each clinical study site. Of the 704 clinical isolates, 406 (57.7%) were
fresh isolates (never frozen and tested within 7 days from isolation in culture), 131 (18.6%) were recent
isolates (7 days from isolation in culture or frozen for less than 1 year before testing), and 167 (23.7%)
were stock (frozen for 1 to 3 years before testing). All clinical isolates were subcultured on blood agar
before testing; frozen isolates were subcultured twice before testing. A single 0.5 McFarland suspension
was prepared for Etest and reference BMD testing. For mucoid isolates, a 1.0 McFarland suspension was
prepared for Etest and the 0.5 McFarland was used for the reference BMD. An inoculum density check
as described above was performed on a minimum of 10% of fresh clinical isolates at each study site.
Data analysis. Clinical and challenge isolates tested for MEV susceptibility by Etest MEV and
reference BMD were included in the performance evaluation. Essential agreement (EA) was defined as
the percentage of total isolates where the test and reference methods were within one doubling dilution
of each other. Evaluable essential agreement was defined as the percentage of test results that were on
scale and in essential agreement with the reference method. Category agreement (CA) was defined as
the percentage of total test results in agreement with interpretive results (susceptible, intermediate, and
resistant) of the reference method. The very major error (VME) rate was defined as the percentage of
isolates interpreted as resistant by the reference method and susceptible by the Etest method. The major
error (ME) rate was defined as the percentage of isolates interpreted as susceptible by the reference
method but resistant by the Etest method. The minor error (mE) rate was defined as the percentage of
total isolates for which the reference method interpretation was resistant or susceptible and the Etest
method interpretation was intermediate or vice versa. The FDA currently recognizes the CLSI supplement
M100 29th edition breakpoints for MEV and Enterobacterales (www.fda.gov/STIC). The performance of
Etest MEV was evaluated using CLSI/FDA or EUCAST interpretative criteria (Table 1) as indicated.
RESULTS
Reproducibility of Etest MEV. Twelve on-scale isolates (Citrobacter freundii, n  1;
Klebsiella [formerly Enterobacter] aerogenes, n  1; Enterobacter cloacae complex, n  1;
E. coli, n  3; K. pneumoniae, n  3, P. aeruginosa, n  2; and Serratia marcescens, n 
1) were tested at the UCLA, WU, and Cardiff study sites as described in Materials and
Methods. A total of 324 tests (108/site) were performed. Mode values of MEV MICs for
each isolate tested across all sites are shown in Table 2. The reproducibility rate for all
strains, including Pseudomonas aeruginosa, between sites was 99.7%, with 323 tests
within 1 doubling dilution of strain-specific modal values. Among only Enterobacterales,
TABLE 1 CLSI/FDA and EUCAST interpretive criteria for meropenem-vaborbactama
Organism(s)
MIC (g/ml)b
CLSI/FDA
criteria
EUCAST
criteria
S I R S I R
Enterobacterales 4/8 8/8 16/8 8/8 8/8
Pseudomonas aeruginosa 8/8 8/8
aCLSI MEV breakpoints are as reported in CLSI supplement M100, 29th edition (11). FDA breakpoints are
available at www.fda.gov/STIC. EUCAST MEV breakpoints are as reported in reference 12.
bAbbreviations: S, susceptible; I, intermediate; R, resistant.
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the reproducibility rate was 99.6%, with 269 of 270 tests within 1 doubling dilution of
strain-specific modal values.
QC of Etest MEV. For quality control (QC) of Etest MEV, five (5) quality control
organisms were tested a minimum of 20 times by the Etest and broth microdilution
methods throughout the study at all study sites as described in Materials and Methods.
One hundred percent of broth microdilution and Etest results for E. coli ATCC 25922, E.
coli ATCC 35218, P. aeruginosa ATCC 27853, and K. pneumoniae ATCC BAA-1705 quality
control results were within the expected range. Broth microdilution results for K.
pneumoniae ATCC 700603 were out of range in two instances at 2 study sites, resulting
in 97.7% (84/86) of quality control results being within range. All Etest quality control
results for K. pneumoniae ATCC 700603 were within range (86/86; 100%).
Etest MEV challenge study. The accuracy of the Etest MEV was evaluated with 88
challenge isolates (79 Enterobacterales and 9 P. aeruginosa) tested at the Marcy study
site. Twelve (15.2%) Enterobacterales isolates were resistant to MEV by broth microdi-
lution according to CLSI/FDA breakpoints (Table 1). Among all Enterobacterales isolates,
Etest MEV demonstrated 93.7% (74/79) essential agreement and 94.9% (75/79) category
agreement. No very major or major errors were detected, but 5.1% (4/79) minor errors
were observed (Table 3). All individual species tested had 90% essential agreement
and category agreement, with the exception of Proteus mirabilis, for which 50% (2/4)
essential agreement and 75% (3/4) category agreement were observed. Excluding P.
mirabilis, the performance for Etest MEV among Enterobacterales was increased to
96.0% (72/75) essential agreement and category agreement with 0 very major or major
errors and 4.0% (3/75) minor errors.
CLSI/FDA breakpoints have not been established for MEV and P. aeruginosa; accord-
ingly, P. aeruginosa is not included in the U.S. FDA indication for Etest MEV. However,
the European Committee on Antimicrobial Susceptibility Testing (EUCAST) includes
breakpoints for both Enterobacterales and P. aeruginosa (Table 1). When assessed with
EUCAST breakpoints, P. aeruginosa isolates demonstrated 88.9% (8/9) essential agree-
ment and 100% (9/9) category agreement. Only one P. aeruginosa challenge isolate was
resistant to MEV according to EUCAST breakpoints, and neither very major nor major
errors were detected among the challenge isolates tested. When EUCAST breakpoints
were applied to Enterobacterales, 11 challenge isolates were resistant to MEV and the
essential agreement and category agreement of Etest MEV among challenge Entero-
bacterales isolates were 93.7% (74/79) and 96.2% (76/79), respectively, with P. mirabilis
TABLE 2 Reproducibility of Etest MEV
Organism
MIC mode for all
tests (g/ml)
No. of tests with doubling dilution from the mode:
Off scale 2 1 0 1 2 Off scale
Citrobacter freundii 0.016 21 6
Klebsiella (Enterobacter) aerogenes 0.032 8 19
Enterobacter cloacae 0.032 7 18 1 1
Escherichia coli
Strain A 0.016 16 11
Strain B 0.016 21 6
Strain C 0.016 27
Klebsiella pneumoniae
Strain A 0.5 1 24 2
Strain B 0.125 3 24
Strain C 0.032 26 1
Pseudomonas aeruginosa
Strain A 1.0 26 1
Strain B 0.5 8 19
Serratia marcescens 0.064 9 18
Total 0 0 36 259 28 1 0
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included, with 18.2% (2/11) very major errors and 1.5% (1/68) major errors. Excluding
P. mirabilis, Etest MEV demonstrated 96% (72/75) essential agreement, 97.3% (73/75)
category agreement with 18.2% (2/11) very major errors and 0 major errors.
Clinical performance of Etest MEV. To evaluate the performance of Etest MEV, a
total of 704 clinical isolates (550 Enterobacterales and 154 P. aeruginosa) were tested at
the UCLA (n  242), WU (n  240), and Cardiff (n  222) study sites. Among
Enterobacterales, 2 clinical isolates were not susceptible (1 was intermediate and 1 was
resistant) to MEV by broth microdilution according to CLSI/FDA interpretive criteria.
essential agreement was 92.2% (507/550), and category agreement was 99.8% (549/
550), with 0% (0/1) very major error, 0% (0/548) major error, and 0.2% (1/550) minor
error rates. The majority of individual species tested demonstrated essential agreement
of 90%, with the exception of members of the Morganellaceae family, including
Morganella morganii (83.3% EA), P. mirabilis (32.3%), Providencia rettgeri (81.0%), and
Providencia stuartii (90.0%). Category agreement for all of the Morganellaceae, including
P. mirabilis, was 100%. Given the poor essential agreement rate of Etest MEV for P.
mirabilis, this species is specifically excluded from the list of FDA indicated-for-use
species and should not be used for Etest MEV MIC determination. Excluding P. mirabilis,
Enterobacterales clinical isolates had 95.8% (497/519) essential agreement and 99.8%
(518/519) category agreement, with 0% very major and major errors and a minor error
rate of 0.2% (1/519).
EUCAST MEV breakpoints for Enterobacterales and P. aeruginosa do not include an
“intermediate” category; rather, isolates with MICs of 8 g/ml are susceptible, while
those with MICs of 8 g/ml are resistant (Table 1). When interpreted using EUCAST
breakpoints, 1 Enterobacterales and 15 P. aeruginosa clinical isolates were resistant to
MEV. Etest MEV demonstrated 95.8% EA, 100% CA, 0% VME, and 0% ME for all
Enterobacterales (excluding P. mirabilis). Of the 154 clinical P. aeruginosa isolates tested,
15 (9.7%) were resistant to MEV by broth microdilution. Etest MEV demonstrated 93.5%
(144/154) essential agreement and 97.4% (150/154) category agreement, with 0% very
major error and 2.9% (4/139) major error rates with P. aeruginosa isolates. The overall
performance of Etest MEV, including all clinical and challenge isolates of all species
(Enterobacterales and P. aeruginosa, but excluding P. mirabilis) was 95.2% EA, 99.2% CA,
7.1% VME, and 0.5% ME. Using EUCAST breakpoints, Etest MEV did not meet the
acceptance criterion of the allowable very major error rate of 3% for either Enterobac-
terales alone (16.7%) or Enterobacterales combined with P. aeruginosa (7.1%). Given the
high rate of very major errors for Enterobacterales isolates that are otherwise in essential
agreement (95.8%) with the reference method, in the absence of an intermediate
interpretive category, we suggest that testing should be repeated using an alternative
testing/reference method prior to reporting results for Enterobacterales when the Etest
MEV MIC is at or near (within 1 doubling dilution of) the EUCAST breakpoint, 8 g/ml.
Molecular characterization of MEV-resistant Enterobacterales tested with Etest
MEV. Among 629 clinical and challenge isolates of Enterobacterales tested, 12 challenge
isolates and 1 clinical isolate were resistant to MEV by broth microdilution according to
CLSI/FDA breakpoints. MEV-resistant isolates were identified as E. coli (2 isolates) and K.
pneumoniae (11 isolates). The molecular characterization of these isolates is listed in
Table 4. Nine of the 13 isolates harbored metallo--lactamases, (7, NDM; 2, VIM); it has
been well established that MEV does not have activity against metallo--lactamases.
DISCUSSION
To facilitate the clinical use of new antimicrobial agents, it is crucial that clinical
laboratories have the ability to perform susceptibility testing for these agents. The
reference broth microdilution method is impractical for most clinical settings, and thus
the availability of commercial methods such as gradient diffusion can facilitate suscep-
tibility testing in clinical microbiology labs as part of routine practice. Here, we
evaluated the performance of Etest MEV (bioMérieux, Marcy l’Etoile, France) compared
to the broth microdilution reference method according to CLSI/FDA and EUCAST
breakpoints for Enterobacterales and P. aeruginosa isolates. Overall, Etest MEV met FDA
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performance criteria, demonstrating 95.8% essential agreement and 99.3% category
agreement with no very major or major errors observed for clinical and challenge
Enterobacterales, excluding P. mirabilis. Etest MEV demonstrated unacceptable perfor-
mance characteristics with clinical and challenge isolates of P. mirabilis, with 34.4%
essential agreement, and is thus excluded from the FDA indication for use (9).
Prior data on the accuracy of gradient diffusion methods for MEV are limited. One
previous study has reported on research-use-only (RUO) product versions of MEV
gradient diffusion strips from bioMérieux and LioFilchem compared to broth microdi-
lution for 120 isolates of carbapenem-resistant Enterobacterales (CRE), including K.
pneumoniae (86 isolates), Enterobacter cloacae (17), E. coli (10) and K. aerogenes (7) (10).
In that study, RUO Etest MEV displayed essential agreement of 82% and category
agreement of 90%. However, the RUO Etest MEV had one very major error, two major
errors, and three minor errors (10). It is important to note that these data were
conducted with a prior iteration (RUO) of Etest MEV. Here, in a large, multicenter study,
we illustrated the performance characteristics of the in vitro diagnostic (IVD) Etest MEV:
95.8% and 99.3%, essential agreement and category agreement, respectively; 0 major
and very major errors, and 0.7% minor errors for 594 clinical and challenge isolates of
Enterobacterales (excluding P. mirabilis). Given the expedited timeline of FDA clearance
of the IVD Etest MEV and superior performance of the IVD product, the use of the RUO
assay is discontinued.
To our knowledge, this is the first report of reduced essential agreement of MEV
gradient diffusion strips compared to broth microdilution for P. mirabilis isolates. This
is an interesting and unexpected finding. Members of the Morganellaceae family were
not included in previous studies evaluating RUO gradient diffusion strips (10), and it is
not clear whether this finding is specific to the IVD bioMérieux Etest gradient diffusion
method. While P. mirabilis isolates were included in the clinical trials of other FDA-
cleared gradient diffusion strips with no contraindication for use with P. mirabilis
isolates indicated in the labeling, species-specific performance data were not shown (5).
A future head-to-head study comparing the performance characteristics of the IVD
versions of gradient diffusion strips for P. mirabilis from multiple manufacturers is
needed to fully resolve this question.
MEV resistance is rare among Enterobacterales worldwide but is more prevalent in
CRE, in particular those that possess a metallo-beta-lactamase (9). In keeping with this
epidemiology, a limitation of this study is the lack of Enterobacterales isolates resistant
to MEV, reflecting the relative rarity of resistant strains at the clinical study sites. Only
13 resistant Enterobacterales isolates were included, 12 of which were challenge isolates
that were limited to E. coli and K. pneumoniae; the sole clinical isolate resistant to MEV
was identified as K. pneumoniae. Evaluation of additional resistant isolates, such as
TABLE 4 Molecular characterization of MEV-resistant Enterobacterales tested with Etest MEV
Isolate Type
MIC by:
Molecular characterizationEtest BMD
Escherichia coli Challenge 8a 16 NDM-7, CMY-42
64 64 NDM-5, TEM-1B, CMY-42
Klebsiella pneumoniae Challenge 8a 64 NDM-1, OXA-9, TEM-1A, CTX-M15, SHV-11, OXA-1
64 64 NDM-1, CMY-4, CTX-M15, SHV-11, OXA-10
8 16 OXA-181, CTX-M15, SHV-26
64 64 NDM-1, OXA-232, OXA-9, TEM-1A, CTX-M15, SHV-11, OXA-1
64 64 OXA-232, CTX-M15, SHV-1, OXA-1
64 64 VIM-1, SHV
64 64 VIM-1, SHV-11
64 64 TEM, SHV, CTX-M15, OXA-48
64 64 TEM, SHV, NDM-1, CTX-M15, OXA-232
16 32 NDM-1, TEM, SHV, CTX-M15, CMY
Clinical 64 64 OXA-48
aThe isolate resulted in very major errors when assessed with EUCAST breakpoints.
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those included in the CDC’s AR isolate bank, may have improved the assessment of
Etest MEV with MEV-resistant isolates. This study also has many strengths. A large
number of clinical isolates (704), including Enterobacterales (550) and P. aeruginosa
(154), were tested across four independent, geographically diverse study sites. Addi-
tionally, Etest MEV performance was evaluated using the CLSI reference method, broth
microdilution. Finally, this rigorous analysis also evaluated performance with CLSI/FDA
and EUCAST MEV breakpoints.
Overall, we conclude that using CLSI/FDA breakpoints, the bioMérieux Etest MEV
showed substantial equivalence for Enterobacterales compared to the reference
method, broth microdilution, with the exception of P. mirabilis, where essential agree-
ment was below acceptance criteria. Importantly, Etest MEV did not have acceptable
performance when EUCAST breakpoints were applied, indicating that they should not
be used with Etest MEV. Although resistance to MEV is rare in Enterobacterales, it does
occur, highlighting the need for susceptibility testing when this antimicrobial agent is
used clinically. Given the relative ease of use and the strong performance characteris-
tics, these data support the use of the bioMérieux Etest MEV in routine clinical practice
with only CLSI/FDA breakpoints.
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